Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruitingRare disease

Study on the Safety and Effects of STAR-0215 for Adults with Hereditary Angioedema

Verified siteInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a condition known as Hereditary Angioedema (HAE), which is a rare genetic disorder that causes sudden and severe swelling in various parts of the body. The study is investigating a new treatment called STAR-0215, which is administered as a sterile solution through a small injection under the skin, known as subcutaneous use. The main goal of the study is to evaluate the safety and tolerability of this treatment in adults with Type I or Type II HAE.

Participants in the trial will receive either a single dose or multiple doses of STAR-0215. Throughout the study, researchers will monitor participants for any side effects and changes in their health, such as vital signs and laboratory test results. The study will also look at how often HAE attacks occur, how severe they are, and how long they last. Additionally, the study will measure the levels of STAR-0215 in the blood and check for any immune response to the treatment.

The trial is expected to continue until October 2024, with recruitment having started in September 2023. This research aims to provide valuable information about the potential of STAR-0215 as a treatment option for people living with Hereditary Angioedema, potentially improving their quality of life by reducing the frequency and severity of swelling episodes.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial assessment

    Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes verifying a documented diagnosis of hereditary angioedema (HAE) and ensuring the participant is at least 18 years old.

    The participant must have experienced at least two HAE attacks during the run-in period, as confirmed by an investigator.

  2. Step 2

    Informed consent

    The participant is required to read, understand, and sign an informed consent form. This document outlines the study's purpose, procedures, and potential risks.

  3. Step 3

    Medication administration

    The study involves the administration of STAR-0215, a sterile solution, through subcutaneous injection. This means the medication is injected under the skin.

    The study includes both single and multiple dose phases to assess the safety and tolerability of the medication.

  4. Step 4

    Monitoring and evaluation

    Throughout the trial, the participant's health is closely monitored. This includes tracking any adverse events, changes in vital signs, and results from physical examinations and laboratory tests.

    The study also evaluates the frequency and severity of HAE attacks, as well as the duration of these attacks.

  5. Step 5

    End of trial

    The trial is expected to conclude by October 20, 2024. At the end of the study, a final assessment is conducted to evaluate the overall impact of STAR-0215 on the participant's condition.

Who can join the trial?

5 criteria

  • Must be at least 18 years old at the time of screening.
  • Must be willing and able to read, understand, and sign the approved informed consent form. This is a document that explains the study and what participation involves.
  • Must have a documented diagnosis of **Hereditary Angioedema (HAE)**, which is a condition that causes episodes of swelling. This includes:
    • A clinical history that matches HAE, such as swelling episodes that occur under the skin or in mucous areas, without itching or hives.
    • First symptoms of swelling started at age 30 or younger, or there is a family history of HAE Type I or II.
    • Must have experienced at least 2 HAE attacks during the initial period of the study, as confirmed by a study investigator. An HAE attack is a period when the swelling symptoms occur.

Who cannot join the trial?

10 criteria

  • Participants who have any other serious health conditions that could interfere with the study.
  • Individuals who are currently participating in another clinical trial.
  • People who have had a recent surgery or are planning to have surgery during the study period.
  • Participants who are pregnant or breastfeeding.
  • Individuals with a history of drug or alcohol abuse.
  • People who have an allergy to the study medication or its ingredients.
  • Participants who are unable to comply with the study procedures or follow-up visits.
  • Individuals who have received certain medications that could affect the study results.
  • People with a history of certain heart conditions.
  • Participants who have uncontrolled high blood pressure.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

STAR-0215 is a medication being studied for its safety and tolerability in people with hereditary angioedema, a condition that causes sudden swelling. The trial is investigating how the body processes and responds to this medication when given in single and multiple doses under the skin. The study aims to understand how well the medication works and if it causes any side effects.

What is already known about the treatment

STAR-0215 – This medication is administered subcutaneously, meaning it is injected under the skin. It is currently being studied in clinical trials to evaluate its safety and effectiveness for treating hereditary angioedema (HAE), a rare genetic condition that causes severe swelling. STAR-0215 is designed to prevent these swelling attacks by targeting specific proteins involved in the inflammatory process. It belongs to a class of drugs known as monoclonal antibodies, which are engineered to interact with specific molecules in the body to modify disease processes.

Investigated diseases

Hereditary Angioedema – Hereditary Angioedema (HAE) is a rare genetic disorder characterized by recurrent episodes of severe swelling. This swelling can occur in various parts of the body, including the hands, feet, face, and airway, as well as the intestinal walls, leading to abdominal pain. The condition is caused by a deficiency or dysfunction of a protein called C1 inhibitor, which helps regulate blood vessel permeability. During an attack, the lack of this protein leads to an overproduction of bradykinin, a peptide that increases blood vessel permeability, resulting in swelling. The frequency and severity of attacks can vary greatly among individuals, with some experiencing frequent and severe episodes, while others have milder symptoms. Swelling episodes can last from several hours to a few days and can be triggered by stress, trauma, or hormonal changes.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase ITrial ID2022-502953-32-01Protocol codeSTAR-0215-201Estimated enrolment62 patientsSponsorAstria Therapeutics Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.